Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 195
interventional 152
Observational 37
Registry 6

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 90
Drug|placebo 32
Biological 16
Biological|placebo 5
Other 3
Biological|Drug 2
Device 1
Drug|Other 1
Drug|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
China 29
United States 28
NA 14
France 4
Italy 4
Egypt 3
Japan 3
Korea, Republic of 3
Mexico 3
United Kingdom 3
Australia 2
Canada 2
Denmark 2
Hong Kong 2
Norway 2
Australia|Belgium|Bulgaria|Czechia|Netherlands|New Zealand|Poland|Singapore|Slovakia|South Africa|Ukraine 1
Australia|Bulgaria|Czechia|Georgia|Germany|Italy|Moldova, Republic of|Poland|Romania|Spain|United Kingdom 1
Austria 1
Austria|Belgium|Czechia|France|Germany|Hungary|Poland|Spain|Ukraine|United Kingdom 1
Belgium 1
Brazil 1
Bulgaria|Czechia|Germany|Hungary|Serbia|Spain 1
Bulgaria|Romania|Serbia 1
Canada|Netherlands 1
Czechia|Germany|Hungary|Poland 1
Georgia|Moldova, Republic of|Poland 1
Germany 1
Germany|Greece|Hong Kong|Korea, Republic of|New Zealand|Pakistan|Poland|Romania|Russian Federation|Slovenia|Taiwan|Thailand|United Kingdom 1
Germany|Italy|Poland|Russian Federation|Ukraine|United Kingdom 1
Germany|Russian Federation 1
Iran, Islamic Republic of 1
Netherlands 1
Poland 1
Russian Federation 1
Russian Federation|Spain|United Kingdom 1
Switzerland 1
Taiwan 1
Thailand 1
Turkey|United States|Australia|Belgium|Brazil|Canada|Czechia|France|Hungary|Israel|Mexico|Poland|Russian Federation|South Africa|Spain|Switzerland|United Kingdom 1
Ukraine 1
Ukraine|Spain|United States|Belgium|France|Hungary|Italy|Japan|Netherlands|Poland|Russian Federation 1
United States|Argentina|Czech Republic|Germany|Hong Kong|Israel|Italy|Poland|Russian Federation|Spain|Taiwan|Thailand|United Kingdom 1
United States|Argentina|India 1
United States|Australia|Austria|Bulgaria|Canada|Czechia|Denmark|Hungary|Italy|Netherlands|Norway|Poland|Romania|Spain|United Kingdom 1
United States|Australia|Austria|Canada|China|Czech Republic|Denmark|Finland|France|Germany|Greece|Hong Kong|Italy|Korea, Republic of|Netherlands|New Zealand|Pakistan|Peru|Poland|Romania|Russian Federation|Slovakia|Slovenia|Spain|Sweden|Taiwan|Thailand|Tunisia|Ukraine|United Kingdom|Vietnam 1
United States|Australia|Bulgaria|Canada|Czechia|Netherlands|Norway|United Kingdom 1
United States|Australia|Canada 1
United States|Australia|Canada|Denmark|Hungary|Italy|Netherlands|United Kingdom 1
United States|Australia|Canada|Georgia|Moldova, Republic of|Poland|Russian Federation|United Kingdom 1
United States|Australia|Canada|Spain 1
United States|Australia|Czechia|France|Germany|Italy|Poland|Spain|United Kingdom 1
United States|Australia|New Zealand 1
United States|Austria|Brazil|Chile|France|Greece|Italy|Japan|Oman|Russian Federation|Spain|Switzerland|Turkey|United Kingdom 1
United States|Austria|Bulgaria|Czechia|Germany|Norway|Poland|Romania|Spain 1
United States|Austria|Canada|China|Czech Republic|Denmark|Finland|France|Germany|Greece|Hong Kong|India|Italy|Netherlands|New Zealand|Peru|Poland|Russian Federation|Slovakia|Spain|Taiwan|Tunisia|Ukraine|United Kingdom|Vietnam 1
United States|Belgium|France|Germany|Hungary|Italy|Netherlands|Poland|Spain 1
United States|Belgium|Germany|India|Israel|Poland|Romania|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
United States|Canada|France|Netherlands|Spain|United Kingdom 1
United States|Canada|India|Puerto Rico 1
United States|Czech Republic|France|Germany|Hong Kong|Hungary|India|Italy|Korea, Republic of|Pakistan|Russian Federation 1
United States|Germany|United Kingdom 1
United States|Greece|Korea, Republic of|Poland|Spain 1
United States|Italy|Poland|Russian Federation 1

Sites per Study

Site_count Study_Count
1 82
2 2
3 6
4 3
5 5
6 2
7 3
8 1
9 1
10 2
11 4
12 2
14 2
15 1
17 3
18 1
19 1
20 2
21 1
22 2
23 1
25 2
27 1
28 2
29 1
30 3
31 1
33 2
34 1
35 1
42 1
45 1
47 1
48 1
51 1
52 1
55 1
59 1
78 1
110 1
115 1

Phase

Phase Study_Count
Phase 3 58
Phase 2 39
Phase 1 17
Phase 4 17
N/A 8
Phase 1/Phase 2 8
Phase 2/Phase 3 4
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 54
2 59
3 15
4 7
5 2
10 2
25 1
NA 12

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 22 10.000 12.0000 16.0 8.0000 17.0 9.0000 15.0000
1st Qu. 22 15.000 28.7500 20.5 26.0000 18.5 48.0000 30.0000
Median 22 42.500 36.0000 33.0 45.0000 27.5 81.0000 62.0000
Mean 22 96.875 38.3125 34.5 60.4359 43.0 107.7018 105.6471
3rd Qu. 22 100.000 44.0000 41.5 66.0000 52.0 155.0000 169.0000
Max. 22 450.000 84.0000 70.0 250.0000 100.0 414.0000 288.0000

Trial Group Type

group_type Group_Count
Experimental 206
Active Comparator 43
Placebo Comparator 35
NA 12
Other 8
No Intervention 7
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 78
Single Group Assignment 57
Crossover Assignment 6
Sequential Assignment 6
NA 5

Primary Purpose

primary_purpose Study_Count
Treatment 141
Other 4
Diagnostic 2
Supportive Care 2
Basic Science 1
Prevention 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
NA 11
France 7
United States 5
China 4
Italy 3
Japan 2
Austria|Belgium|France|Germany|Greece|Netherlands|Spain|United Kingdom 1
Korea, Republic of 1
Spain 1
United States|Australia|Bulgaria|Canada|Czech Republic|France|Germany|Hong Kong|Hungary|India|Italy|Pakistan|Peru|Poland|Puerto Rico|Russian Federation|Spain|Sweden|Tunisia|Ukraine|United Kingdom 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 26
2 1
3 1
6 2
13 1
14 1
22 1
29 2
36 1
72 1

Enrollment Metrics

Measure Observational
Min 10.0000
1st Qu 41.0000
Median 107.0000
Mean 997.4324
3rd Qu 326.0000
Max 20000.0000

Observation Model

observational_model Study_Count
Cohort 19
Case-Only 8
Case-Control 4
Case Control 2
Other 2
NA 2

Time Perspective

time_perspective Study_Count
Prospective 21
Retrospective 10
Cross-Sectional 3
NA 3

Registries

Studies by Country

Country Study_Count
France 2
Australia|Colombia|Korea, Republic of|Kuwait|Malaysia|Singapore|Taiwan|Thailand|Turkey|Uruguay 1
Austria 1
NA 1
United States 1

Sites per Study

Site_count Study_Count
1 5
44 1

Enrollment Metrics

Measure Registries
Min 1.00
1st Qu 50.00
Median 116.50
Mean 264.00
3rd Qu 420.75
Max 800.00

Registry Model

observational_model Study_Count
Cohort 5
Other 1

Time Perspective

time_perspective Study_Count
Prospective 6

Follow-up

target_duration Study_Count
10 Years 1
12 Months 1
2 Months 1
24 Months 1
4 Years 1
6 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03304288 The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT03304288 Recruiting Peking University People’s Hospital 2020-08-31
NCT03275740 A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 https://ClinicalTrials.gov/show/NCT03275740 Recruiting Pfizer 2020-10-21
NCT03275454 A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT03275454 Recruiting Sanofi 2022-05-31
NCT03258866 The Study of Different Dose Rituximab in the Treatment of ITP https://ClinicalTrials.gov/show/NCT03258866 Completed Shandong University 2015-12-31
NCT03229746 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT03229746 Completed Assiut University 2018-06-01
NCT03222843 Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient https://ClinicalTrials.gov/show/NCT03222843 Recruiting Jiangsu HengRui Medicine Co., Ltd. 2020-06-30
NCT03201848 The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT03201848 Recruiting Qidong Gaitianli Medicines Co., Ltd 2021-12-31
NCT03177629 H. Pylori Eradication for Moderate ITP https://ClinicalTrials.gov/show/NCT03177629 Recruiting Seoul National University Hospital 2020-06-30
NCT03172676 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT03172676 Recruiting Assiut University 2020-06-01
NCT03156452 Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate https://ClinicalTrials.gov/show/NCT03156452 Active, not recruiting University Hospitals Bristol NHS Foundation Trust 2020-02-13
NCT03154385 Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT03154385 Completed Assistance Publique - Hôpitaux de Paris 2019-11-13
NCT03102593 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP https://ClinicalTrials.gov/show/NCT03102593 Completed argenx BVBA 2019-04-09
NCT02287649 Polymorphism and Auto-reactive B and T Cells Subsets in Adult’s Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT02287649 Completed Assistance Publique - Hôpitaux de Paris 2015-10-02
NCT03010202 The PROLONG Trial - Rituximab Maintenance Therapy in ITP https://ClinicalTrials.gov/show/NCT03010202 Recruiting Ostfold Hospital Trust 2023-12-31
NCT02914054 Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone https://ClinicalTrials.gov/show/NCT02914054 Completed Isfahan University of Medical Sciences 2017-09-15
NCT02868099 Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT02868099 Completed Kyowa Hakko Kirin China Pharmaceutical Co., LTD. 2017-02-28
NCT02868060 Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT02868060 Completed Kyowa Hakko Kirin China Pharmaceutical Co., LTD. 2017-08-31
NCT02859909 This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT02859909 Completed Biotest 2018-12-31
NCT02760251 Immunomodulation With Romiplostim in Young Adults With ITP https://ClinicalTrials.gov/show/NCT02760251 Completed University Hospital, Basel, Switzerland 2019-07-31
NCT02718716 Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT02718716 Completed UCB Pharma 2019-02-28
NCT03395210 A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT03395210 Recruiting Principia Biopharma Inc. 2021-06-30
NCT02402998 Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia https://ClinicalTrials.gov/show/NCT02402998 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-05-22
NCT02391272 A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy https://ClinicalTrials.gov/show/NCT02391272 Completed Shandong University 2015-11-30
NCT02351622 Caffeic Acid Tablets as a Second-line Therapy for ITP https://ClinicalTrials.gov/show/NCT02351622 Completed Shandong University 2013-12-31
NCT02334813 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT02334813 Completed University Hospital, Essen 2015-01-31
NCT02281370 Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects https://ClinicalTrials.gov/show/NCT02281370 Completed GlaxoSmithKline 2014-12-24
NCT02279173 Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT02279173 Completed Amgen 2018-08-30
NCT02273960 Study to Evaluate Safety and Efficacy in Adult Subjects With ITP https://ClinicalTrials.gov/show/NCT02273960 Completed Bristol-Myers Squibb 2018-01-22
NCT02201290 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT02201290 Completed Novartis 2017-07-04
NCT02153060 An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT02153060 Completed Shandong University 2015-01-31
NCT02139501 An Investigation of rhTPO With Different Frequencies in the Management of ITP https://ClinicalTrials.gov/show/NCT02139501 Completed Shandong University 2015-01-31
NCT02077192 Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT02077192 Active, not recruiting Rigel Pharmaceuticals 2020-03-31
NCT02076412 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT02076412 Completed Rigel Pharmaceuticals 2016-08-31
NCT02076399 A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT02076399 Completed Rigel Pharmaceuticals 2016-04-21
NCT02063789 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT02063789 Completed Green Cross Corporation 2016-04-30
NCT01289509 A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects https://ClinicalTrials.gov/show/NCT01289509 Completed Eisai Inc. 2011-03-31
NCT04274452 A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT04274452 Recruiting argenx BVBA 2021-09-01
NCT01988506 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases https://ClinicalTrials.gov/show/NCT01988506 Recruiting Assistance Publique - Hôpitaux de Paris 2020-08-13
NCT01963260 Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) https://ClinicalTrials.gov/show/NCT01963260 Completed Merck Sharp & Dohme Corp. 2015-04-26
NCT01880047 Safety and Efficacy of Eltrombopag at Escalated Doses https://ClinicalTrials.gov/show/NCT01880047 Completed Weill Medical College of Cornell University 2017-02-15
NCT01762761 Eltrombopag Phase III Study In Chinese Chronic ITP Patients https://ClinicalTrials.gov/show/NCT01762761 Completed Novartis 2014-06-05
NCT01734044 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP https://ClinicalTrials.gov/show/NCT01734044 Completed Shandong University 2014-07-31
NCT01730352 Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients https://ClinicalTrials.gov/show/NCT01730352 Completed Federal University of São Paulo 2011-05-31
NCT01719692 Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01719692 Completed Institute of Hematology & Blood Diseases Hospital 2015-10-31
NCT01713855 Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT01713855 Completed Neufeld, Ellis J, MD, PhD NA
NCT01713738 Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT01713738 Completed Neufeld, Ellis J, MD, PhD 2005-12-31
NCT01667263 The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01667263 Completed Peking University People’s Hospital 2016-07-01
NCT01652599 Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT https://ClinicalTrials.gov/show/NCT01652599 Completed Hospital Universitario Dr. Jose E. Gonzalez 2013-06-30
NCT01621204 A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients https://ClinicalTrials.gov/show/NCT01621204 Completed McMaster University 2019-06-30
NCT01610180 Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) https://ClinicalTrials.gov/show/NCT01610180 Completed Fondazione Progetto Ematologia 2018-06-30
NCT01568333 A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01568333 Completed Shandong University 2017-10-31
NCT01549054 A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 https://ClinicalTrials.gov/show/NCT01549054 Completed Eisai Inc. 2012-06-30
NCT01525836 rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP https://ClinicalTrials.gov/show/NCT01525836 Completed Shandong University 2013-12-31
NCT01520909 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. https://ClinicalTrials.gov/show/NCT01520909 Completed GlaxoSmithKline 2014-01-31
NCT01506414 Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT01506414 Completed Shandong University 2013-08-31
NCT01444417 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients https://ClinicalTrials.gov/show/NCT01444417 Completed Amgen 2015-02-28
NCT01438840 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) https://ClinicalTrials.gov/show/NCT01438840 Completed Eisai Inc. 2013-11-30
NCT01437384 Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. https://ClinicalTrials.gov/show/NCT01437384 Completed Eisai Inc. 2012-03-31
NCT01390649 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT01390649 Completed CSL Behring 2014-09-30
NCT01356511 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT01356511 Completed Shandong University 2014-05-31
NCT01327872 Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects https://ClinicalTrials.gov/show/NCT01327872 Completed Eisai Inc. 2011-04-30
NCT04368598 The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP https://ClinicalTrials.gov/show/NCT04368598 Recruiting Peking University People’s Hospital 2020-12-31
NCT04224688 A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT04224688 Recruiting UCB Pharma 2022-07-31
NCT04217148 The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT04217148 Recruiting Peking University People’s Hospital 2022-12-31
NCT04132050 A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 https://ClinicalTrials.gov/show/NCT04132050 Recruiting Kissei Pharmaceutical Co., Ltd. 2021-12-31
NCT04089267 Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT04089267 Completed Shenyang Sunshine Pharmaceutical Co., LTD. 2018-12-31
NCT04083014 Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia https://ClinicalTrials.gov/show/NCT04083014 Recruiting Peking Union Medical College Hospital 2022-08-20
NCT04056195 Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT04056195 Recruiting Oscotec Inc. 2021-02-28
NCT04039477 A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP https://ClinicalTrials.gov/show/NCT04039477 Recruiting Kezar Life Sciences, Inc. 2020-12-31
NCT04014413 Safety and Efficacy of Fecal Microbiota Transplantation https://ClinicalTrials.gov/show/NCT04014413 Recruiting Chinese University of Hong Kong 2023-10-31
NCT04014166 Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT04014166 Recruiting Institute of Hematology & Blood Diseases Hospital 2021-12-31
NCT03951623 The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients https://ClinicalTrials.gov/show/NCT03951623 Recruiting Hutchison Medipharma Limited 2021-12-31
NCT03939637 Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children https://ClinicalTrials.gov/show/NCT03939637 Recruiting Baylor College of Medicine 2022-05-01
NCT03866798 Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT03866798 Recruiting Octapharma 2022-03-31
NCT03866577 Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients https://ClinicalTrials.gov/show/NCT03866577 Recruiting Momenta Pharmaceuticals, Inc. 2022-04-30
NCT03830749 Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT03830749 Recruiting Humanity & Health Medical Group Limited 2020-12-31
NCT03771378 Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT03771378 Recruiting Wuhan Union Hospital, China 2020-05-01
NCT03692754 Atorvastatin in Management of Newly Diagnosed ITP https://ClinicalTrials.gov/show/NCT03692754 Recruiting Shandong University 2021-12-01
NCT03603132 A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics https://ClinicalTrials.gov/show/NCT03603132 Completed Jiangsu HengRui Medicine Co., Ltd. 2018-08-17
NCT03524612 A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP https://ClinicalTrials.gov/show/NCT03524612 Recruiting Novartis 2022-06-30
NCT03421184 Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus https://ClinicalTrials.gov/show/NCT03421184 Recruiting University Hospital, Bordeaux 2020-11-30
NCT03412188 The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. https://ClinicalTrials.gov/show/NCT03412188 Recruiting Ain Shams University 2019-11-30
NCT01129024 An Open-label Safety Study of S-888711 https://ClinicalTrials.gov/show/NCT01129024 Completed Shionogi Inc. 2011-08-31
NCT01107951 Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP https://ClinicalTrials.gov/show/NCT01107951 Completed Hospital Universitario Dr. Jose E. Gonzalez 2010-04-30
NCT01098487 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT01098487 Completed GlaxoSmithKline 2014-05-31
NCT01072162 Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect https://ClinicalTrials.gov/show/NCT01072162 Completed GlaxoSmithKline 2010-04-07
NCT01071954 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura https://ClinicalTrials.gov/show/NCT01071954 Completed Amgen 2017-01-12
NCT00909077 The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00909077 Completed Copenhagen University Hospital at Herlev 2012-06-01
NCT00908037 Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00908037 Completed GlaxoSmithKline 2014-02-01
NCT00907478 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) https://ClinicalTrials.gov/show/NCT00907478 Completed Amgen 2014-01-09
NCT00902018 Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00902018 Completed Weill Medical College of Cornell University 2015-09-07
NCT00888901 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag https://ClinicalTrials.gov/show/NCT00888901 Completed Medical University of Vienna 2011-03-31
NCT00860600 Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients https://ClinicalTrials.gov/show/NCT00860600 Completed PhytoHealth Corporation 2011-08-31
NCT04200456 A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT04200456 Recruiting UCB Pharma 2021-12-31
NCT00828750 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00828750 Completed GlaxoSmithKline 2011-02-28
NCT01349790 Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01349790 Completed Octapharma 2013-07-31
NCT04070599 Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura. https://ClinicalTrials.gov/show/NCT04070599 Completed University Hospital, Bordeaux 2014-03-05
NCT03998982 Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP https://ClinicalTrials.gov/show/NCT03998982 Recruiting Shandong University 2020-04-01
NCT04225156 A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). https://ClinicalTrials.gov/show/NCT04225156 Recruiting argenx BVBA 2022-06-30
NCT04188379 A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). https://ClinicalTrials.gov/show/NCT04188379 Recruiting argenx BVBA 2021-06-06
NCT02556814 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP https://ClinicalTrials.gov/show/NCT02556814 Completed Shandong University 2018-03-31
NCT01143038 Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim https://ClinicalTrials.gov/show/NCT01143038 Completed Amgen 2013-09-20
NCT00774202 Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP https://ClinicalTrials.gov/show/NCT00774202 Completed Weill Medical College of Cornell University 2008-02-29
NCT00770562 A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00770562 Completed Hoffmann-La Roche 2008-07-31
NCT00749112 Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias https://ClinicalTrials.gov/show/NCT00749112 Completed Hospital Universitario Dr. Jose E. Gonzalez 2010-08-31
NCT00718692 Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00718692 Completed Symphogen A/S 2011-08-31
NCT00706342 Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00706342 Completed Rigel Pharmaceuticals 2010-04-30
NCT00699140 Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00699140 Completed Grifols Biologicals, LLC 2013-12-31
NCT00688272 Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag https://ClinicalTrials.gov/show/NCT00688272 Completed GlaxoSmithKline 2008-09-25
NCT00657410 Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00657410 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2016-02-29
NCT00625443 Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 https://ClinicalTrials.gov/show/NCT00625443 Completed Eisai Inc. 2009-06-30
NCT00621894 Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation https://ClinicalTrials.gov/show/NCT00621894 Completed GlaxoSmithKline 2009-05-01
NCT00603642 P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00603642 Completed Amgen 2009-04-13
NCT00540423 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00540423 Completed GlaxoSmithKline 2008-12-31
NCT00515203 Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects https://ClinicalTrials.gov/show/NCT00515203 Completed Amgen 2009-03-31
NCT00511147 IGIV Study for Chronic ITP Patients Ages 3-70 https://ClinicalTrials.gov/show/NCT00511147 Completed Grifols Biologicals, LLC 2014-04-30
NCT00508820 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP https://ClinicalTrials.gov/show/NCT00508820 Completed Amgen 2011-01-01
NCT00504075 A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00504075 Completed Bio Products Laboratory 2011-08-31
NCT00487968 Eltrombopag Taste Testing in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT00487968 Completed GlaxoSmithKline NA
NCT00486421 Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00486421 Completed Mayo Clinic 2008-05-31
NCT00475423 A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. https://ClinicalTrials.gov/show/NCT00475423 Completed Hoffmann-La Roche 2011-08-31
NCT00467571 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00467571 Completed Mahidol University 2008-09-30
NCT00451594 High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP https://ClinicalTrials.gov/show/NCT00451594 Completed Cooperative Study Group A for Hematology 2010-12-31
NCT00442871 Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment https://ClinicalTrials.gov/show/NCT00442871 Completed GlaxoSmithKline 2008-01-03
NCT00441090 Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00441090 Completed Eisai Inc. 2009-01-31
NCT00426270 Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults https://ClinicalTrials.gov/show/NCT00426270 Completed Octapharma 2008-09-30
NCT00424177 Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) https://ClinicalTrials.gov/show/NCT00424177 Completed GlaxoSmithKline 2008-08-31
NCT00415532 Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00415532 Completed Amgen 2008-11-07
NCT00392951 Sirolimus for Autoimmune Disease of Blood Cells https://ClinicalTrials.gov/show/NCT00392951 Completed Children’s Hospital of Philadelphia 2016-02-29
NCT00376077 A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. https://ClinicalTrials.gov/show/NCT00376077 Completed The Hospital for Sick Children 2016-03-31
NCT00372892 Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00372892 Completed McMaster University 2010-12-31
NCT00370331 RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag https://ClinicalTrials.gov/show/NCT00370331 Completed GlaxoSmithKline 2008-07-31
NCT00362349 Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients https://ClinicalTrials.gov/show/NCT00362349 Completed CSL Limited 2008-10-31
NCT00359463 Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment https://ClinicalTrials.gov/show/NCT00359463 Completed GlaxoSmithKline 2007-03-07
NCT00351468 EXTEND (Eltrombopag Extended Dosing Study) https://ClinicalTrials.gov/show/NCT00351468 Completed Novartis 2015-07-31
NCT00344149 Rituximab as Second Line Treatment for ITP https://ClinicalTrials.gov/show/NCT00344149 Completed Ostfold Hospital Trust 2014-03-31
NCT00220727 Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP https://ClinicalTrials.gov/show/NCT00220727 Completed Grifols Therapeutics LLC 2003-10-31
NCT00168038 Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10 https://ClinicalTrials.gov/show/NCT00168038 Completed CSL Behring NA
NCT00162006 Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00162006 Completed Shire 2003-12-01
NCT00157079 Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders https://ClinicalTrials.gov/show/NCT00157079 Completed Shire 2003-12-16
NCT00151840 Efficacy and Safety of IVIG-L in ITP Patients https://ClinicalTrials.gov/show/NCT00151840 Completed Sanquin Plasma Products BV NA
NCT00128882 Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D https://ClinicalTrials.gov/show/NCT00128882 Completed University of Aarhus 2008-01-31
NCT00117143 Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00117143 Completed Amgen 2004-07-19
NCT00116688 Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00116688 Completed Amgen 2010-01-31
NCT00111475 Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00111475 Completed Amgen 2004-06-17
NCT00102739 SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00102739 Completed GlaxoSmithKline 2007-01-31
NCT00102336 AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy https://ClinicalTrials.gov/show/NCT00102336 Completed Amgen 2006-12-01
NCT00102323 AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy https://ClinicalTrials.gov/show/NCT00102323 Completed Amgen 2006-09-01
NCT00049725 Daclizumab to Treat Chronic Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT00049725 Completed National Institutes of Health Clinical Center (CC) NA
NCT00002250 A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00002250 Completed NIH AIDS Clinical Trials Information Service NA
NCT00005652 Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00005652 Completed Office of Rare Diseases (ORD) 2007-08-31
NCT00001630 Treatment of Autoimmune Thrombocytopenia (AITP) https://ClinicalTrials.gov/show/NCT00001630 Completed National Institutes of Health Clinical Center (CC) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03820960 Risk Factors for Thrombosis in Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT03820960 Recruiting University Hospital, Toulouse 2020-02-29
NCT03219723 Drug Use Surveillance of Takecab for “Supplement to Helicobacter Pylori Eradication” https://ClinicalTrials.gov/show/NCT03219723 Completed Takeda 2017-04-30
NCT02891109 Regulatory B Cells and Chronic Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT02891109 Completed University Hospital, Brest 2015-09-30
NCT02821572 Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT02821572 Recruiting Centre Hospitalier Universitaire Dijon 2018-10-31
NCT02298075 Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT02298075 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-12-31
NCT02085993 Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training https://ClinicalTrials.gov/show/NCT02085993 Completed Amgen 2015-11-30
NCT02063763 TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients. https://ClinicalTrials.gov/show/NCT02063763 Recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2018-10-31
NCT02042560 Study of Immune Thrombocytopenia Pathogenesis: https://ClinicalTrials.gov/show/NCT02042560 Completed Centre Hospitalier Universitaire Dijon 2015-03-12
NCT01974232 A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013 https://ClinicalTrials.gov/show/NCT01974232 Completed Weill Medical College of Cornell University 2013-06-30
NCT01971684 ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP https://ClinicalTrials.gov/show/NCT01971684 Completed Boston Children’s Hospital 2017-04-30
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01727999 Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics https://ClinicalTrials.gov/show/NCT01727999 Completed Stanford University 2017-02-28
NCT01727232 Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult’s Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01727232 Completed Henri Mondor University Hospital 2012-06-30
NCT01672151 Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01672151 Completed First Affiliated Hospital of Suzhou Medical College 2012-08-31
NCT01668615 Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01668615 Completed First Affiliated Hospital of Suzhou Medical College 2012-08-31
NCT01666795 Autoantibody Specificity and Response to IVIG in ITP https://ClinicalTrials.gov/show/NCT01666795 Completed Shandong University 2013-01-31
NCT01618734 Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety. https://ClinicalTrials.gov/show/NCT01618734 Completed Henri Mondor University Hospital 2012-06-30
NCT01571349 Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT01571349 Completed Samsung Medical Center 2012-12-31
NCT01549184 Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01549184 Completed Henri Mondor University Hospital 2011-12-31
NCT01510873 Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP) https://ClinicalTrials.gov/show/NCT01510873 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2014-01-31
NCT01439321 Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim https://ClinicalTrials.gov/show/NCT01439321 Completed GlaxoSmithKline 2011-06-30
NCT01435525 Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation https://ClinicalTrials.gov/show/NCT01435525 Completed AstraZeneca 2014-03-31
NCT01416311 Drug Use Investigation for REVOLADE (ITP) https://ClinicalTrials.gov/show/NCT01416311 Active, not recruiting Novartis 2020-10-20
NCT04057703 Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia. https://ClinicalTrials.gov/show/NCT04057703 Completed University Hospital, Bordeaux 2016-12-04
NCT04056507 Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT04056507 Completed University Hospital, Bordeaux 2015-09-30
NCT03998059 Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients https://ClinicalTrials.gov/show/NCT03998059 Recruiting Institute of Hematology & Blood Diseases Hospital 2022-01-23
NCT03810352 Association of Platelet Parameters With Bleeding Severity in Children With ITP https://ClinicalTrials.gov/show/NCT03810352 Recruiting Boston Children’s Hospital 2021-02-01
NCT03469661 Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS) https://ClinicalTrials.gov/show/NCT03469661 Recruiting Fundacion CRIS de Investigación para Vencer el Cáncer 2020-04-30
NCT03429660 French Adult Primary Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT03429660 Recruiting University Hospital, Toulouse 2023-05-31
NCT00960713 The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders https://ClinicalTrials.gov/show/NCT00960713 Completed University Hospital, Toulouse 2012-01-31
NCT00861224 Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology https://ClinicalTrials.gov/show/NCT00861224 Completed Amgen 2006-10-31
NCT04070612 National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia. https://ClinicalTrials.gov/show/NCT04070612 Completed University Hospital, Bordeaux 2012-06-08
NCT04005638 Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia https://ClinicalTrials.gov/show/NCT04005638 Recruiting University Hospital, Bordeaux 2022-02-28
NCT04071496 Diagnostic of Chronic Thrombocytopenia https://ClinicalTrials.gov/show/NCT04071496 Completed University Hospital, Bordeaux 2012-03-12
NCT00643929 LENS - Long-term Eltrombopag Observational Study https://ClinicalTrials.gov/show/NCT00643929 Completed GlaxoSmithKline 2013-03-31
NCT00454857 Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00454857 Completed Amgen 2008-06-30
NCT00005570 An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers https://ClinicalTrials.gov/show/NCT00005570 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03123497 Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid’s ITP Tools) https://ClinicalTrials.gov/show/NCT03123497 Recruiting University Hospital, Angers 2020-10-31
NCT02877706 Autoimmune Cytopenias : Midi-Pyrenees Registry https://ClinicalTrials.gov/show/NCT02877706 Recruiting University Hospital, Toulouse 2023-06-30
NCT01970189 The International ITP Registry https://ClinicalTrials.gov/show/NCT01970189 Recruiting South Eastern Sydney Local Health District 2016-12-31
NCT01933035 Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. https://ClinicalTrials.gov/show/NCT01933035 Completed Beth Israel Medical Center 2015-10-31
NCT03576742 Severe Immune Cytopenia Registry Www.Sic-reg.Org https://ClinicalTrials.gov/show/NCT03576742 Recruiting Medical University of Graz 2022-03-08
NCT01064336 Promacta Pregnancy Registry https://ClinicalTrials.gov/show/NCT01064336 Completed GlaxoSmithKline 2014-07-31